Forpracticing hematologists, oncologists, and gastroenterologists in this field, the awareness and early diagnosis of the GI complicationsremain important factors to obtain optimal outcomes in this patient population.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:The gastrointestinal (GI) system is one of the most commonly affected sites during a hematopoietic stem cell transplantation (HSCT)due to toxicities of preparative regimens, the accompanying immunodeficiency, and organ damage caused by graft versus host disease.In this review, we focus on early GI and liver complications following autologous (auto-) and allogeneic (allo-) HSCT and clarify both therisk factors and therapeutic strategies.
📊
Temel Bulgular & Veri:Despite theimprovements in this field during the last decade, treatments for these complications still place a significant burden on both patientsand the physicians treating these patients.
💡
Sonuç & Katkı:Forpracticing hematologists, oncologists, and gastroenterologists in this field, the awareness and early diagnosis of the GI complicationsremain important factors to obtain optimal outcomes in this patient population.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri
Özet
The gastrointestinal (GI) system is one of the most commonly affected sites during a hematopoietic stem cell transplantation (HSCT)due to toxicities of preparative regimens, the accompanying immunodeficiency, and organ damage caused by graft versus host disease.In this review, we focus on early GI and liver complications following autologous (auto-) and allogeneic (allo-) HSCT and clarify both therisk factors and therapeutic strategies. Early GI and liver complications associated with HSCT remain challenging issues. Despite theimprovements in this field during the last decade, treatments for these complications still place a significant burden on both patientsand the physicians treating these patients. GI and liver complications remain some of the causes of mortality associated with HSCT. Forpracticing hematologists, oncologists, and gastroenterologists in this field, the awareness and early diagnosis of the GI complicationsremain important factors to obtain optimal outcomes in this patient population.
🔖
Bu Makaleye Atıf Yap
ATİLLA, E., ATİLLA, P. A., SEVAL, G. C., BEKTAŞ, M., DEMİRER, T. (2019). Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation. Turkish Journal of Gastroenterology, Cilt: 30 - Sayı: 2, 122–131. https://ajindex.com/articles/408796
Mohty B, Mohty M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. Blood Cancer J 2011; 1: e16. [CrossRef] Pedrazzoli P, Ferrante P, Kulekci A, et al. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999. Bone Marrow Transplant 2003; 32: 489-94. [CrossRef] Pedrazzoli P, Ledermann JA, Lotz JP, et al. High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. Ann Oncol 2006; 17: 1479-88. [CrossRef] Sahin U, Toprak SK, Atilla PA, Atilla E, Demirer T. An Overview of infectious complications after allogeneic hematopoietic stem cell transplantation. J Infect Chemother 2016; 22: 505-14. [CrossRef] Demirer T, Buckner CD, Appelbaum FR, et al. High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. Bone Marrow Transplant 1996; 17: 769-74. Billingham RE. The biology of graft-versus-host reactions. Harvey Lectures 1966; 62: 21-78.
Tuncer H, Rana N, Milani C, et al. Gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. World J Gastroenterol 2012; 18: 1851-60. [CrossRef] Giorgi U D, Wandt H, Lioure B, et al. First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors. The experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working party. Bone Marrow Transplant 2004; 34: 1033-7. [CrossRef] Rodrigues FG, Dasilva G, Wener SD. Neutropenic enterocolitis. World J Gastroenterol 2017; 23: 42-7. [CrossRef] Chaudhry HM, Bruce AJ, Wolf RC, et al. The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. Biol Blood Marrow Transplant 2016; 22: 605-16. [CrossRef] Pavletic SZ, Vogelsang GB, Lee SJ. 2014 National institutes of Health consensus Development project on criteria for clinical Trials in chronic Graft-versus-Host Disease: preface to the series. Biol Blood Marrow Transplant 2015; 21: 387-8. [CrossRef] Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838-45.
Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors